论文部分内容阅读
FKI- 0 0 76 A、B和 C是从真菌培养液中筛选 Azole类抗真菌活性增强剂过程中获得的 ,每 6 mm纸片 10μg FKI- 0 0 76 A、B或 1.0μg FKI- 0 0 76 C就显示增强活性。真菌 Talaromyces sp.FKI- 0 0 76培养 5 d后 ,经有机溶媒提取 ,常压 ODS柱层析和制备 HPL C柱层析分离 ,得到 FKI- 0 0 76 A、B和 C纯品。又经过测定其HR- MS、UV、IR、1 H- NMR、1 3C- NMR、DEPT、1 H- 1 H COSY、HMQC和 HMBC等光谱数据。将 FKI- 0 0 76 A的结构定为 BK 2 2 3- A,FKI- 0 0 76 B的结构定为 vermistatin,FKI- 0 0 76 C的结构定为 deoxyfunicone。
FKI- 0 0 76 A, B and C were obtained from a fungal culture medium for the screening of antifungal activity enhancers of Azole, 10 μg FKI-0 0 76 A, B per 6 mm sheet or 1.0 μg FKI-0 0 76 C shows enhanced activity. Fungal Talaromyces sp. FKI- 0 0 76 After culturing for 5 days, it was separated by organic solvent extraction, normal pressure ODS column chromatography and HPL C column chromatography to obtain pure products of FKI-076A, B and C. Further, spectroscopic data such as HR-MS, UV, IR, 1 H-NMR, 1 3C-NMR, DEPT, 1 H- 1 H COZY, HMQC and HMBC were determined. The structure of FKI-0 0 76 A was defined as BK 2 2 3-A, the structure of FKI-0 0 76 B as vermistatin, and the structure of FKI-0 0 76 C as deoxyfunicone.